Biotech News

Bristol Myers Squibb Announces Dividend

BMYBristol-Myers Squibb Company (BMY)BMYBristol-Myers Squibb Company2026-06-17 20:16 ESTEarnings

Bristol Myers Squibb Announces Dividend

June 17, 2026

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company.

The dividend is payable on August 3, 2026, to stockholders of record at the close of business on July 2, 2026.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit us at BMS.com and follow us on LinkedIn , X , YouTube , Facebook , and Instagram .

corporatefinancial-news

Source: Bristol Myers Squibb

Media downloads:

Categories: Press Releases

Open original release

Related news

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

BMYBMYBristol-Myers Squibb Company2026-06-18 10:59 EST

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

BMYBMYBristol-Myers Squibb Company2026-06-02 12:00 EST

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

BMYBMYBristol-Myers Squibb Company2026-06-01 10:59 EST

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

BMYBMYBristol-Myers Squibb Company2026-06-01 10:55 EST

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

BMYBMYBristol-Myers Squibb Company2026-05-30 18:15 EST

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BMYBMYBristol-Myers Squibb Company2026-05-29 12:00 EST

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

BMYBMYBristol-Myers Squibb Company2026-05-27 10:59 EST

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

View all latest news

BMYBristol-Myers Squibb Company

Bristol Myers Squibb is a large-cap biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular disease. The market watches the stock for commercial durability, pipeline replacement, and the pace at which new assets offset lifecycle pressure.

Recent company news

BMYGSK plc2026-07-21 10:28 EST

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

BMYGSK plc2026-07-20 07:00 EST

European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds

BMYFresenius Medical Care Ventures2026-07-20 07:00 EST

Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy

BMYGSK plc2026-07-17 09:00 EST

GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)

Stock data

Close: 60.16 USD
Market cap: 111.21B USD
Exchange: NYSE
Sector: Biopharmaceuticals
Location: Princeton, New Jersey